Market Cap
$11.7B
TXG
10x Genomics, Inc.
$93.00 ▲ +4.78%
Prev close $88.76Market cap$11.7B
ConsensusHold
12-mo target$62.13 (-33.2%)
▲ Neutral
Analyst conviction 5/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)27 New Institutional Positions23 Institutional Exits Genomics & Gene Editing
Snapshot
The big-picture read on TXG right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Hold (45%)
Inst. Holders
50 funds
Inst. Value
$3.9B
Inst. Activity
27 buys / 23 sells
Insider Activity
$0.00 buy / $15.2M sell
Insider Net $
-$15.2M
Social Sentiment
43° Neutral
SEC Reports
18
Price chart 30d +50.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 other
10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times
Sep 22, 2026 Insider
Saxonov Serge sold 2,800 shares
Chief Executive Officer @ $82.37 ($230.6K)
Sep 22, 2026 Insider
Saxonov Serge sold 9,300 shares
Chief Executive Officer @ $80.90 ($752.4K)
Sep 22, 2026 Insider
Sep 11, 2026 SEC Saxonov Serge sold 9,900 shares
Chief Executive Officer @ $81.83 ($810.1K)
Two TXG insiders, including CFO Adam Taich and Director John Stuelpnagel, sold a combined $502K in open-market sales ove
CLUSTER — Impact 3/10
Director John R. Stuelpnagel filed a Form 144 notice of intent to sell 20,000 shares of Class A common stock, with an es
144 — Impact 4/10
A cluster of insider selling at 10x Genomics (TXG) over the past week saw the CEO, CFO, and a director collectively sell
CLUSTER — Impact 4/10
Aug 19, 2026 Event
10x Genomics, Inc. v. Parse Biosciences, Inc.
Court ruling (ca13) — Docket: 25-01618
Analyst ratings buy % +25.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
45% rate it Buy or better · 20 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 29, 2026 | Leerink Partners | MAINTAIN | Market Perform | 49% |
| Sep 28, 2026 | Piper Sandler | MAINTAIN | Neutral | 54% |
| Sep 28, 2026 | Argus Research | INITIATE | Buy | 54% |
| Sep 9, 2026 | UBS | MAINTAIN | Neutral | 55% |
| Sep 1, 2026 | RBC Capital | INITIATE | Sector Perform | 55% |
| Aug 12, 2026 | Stephens & Co. | MAINTAIN | Overweight | 54% |
| Aug 10, 2026 | Piper Sandler | MAINTAIN | Neutral | 54% |
| Aug 10, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Aug 7, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| Aug 7, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 4 | 11 | 0 | 0 | 45% | |
| Aug 1, 2026 | 5 | 4 | 11 | 0 | 0 | 45% | |
| Jul 1, 2026 | 5 | 4 | 11 | 0 | 0 | 45% | |
| Jun 1, 2026 | 5 | 4 | 12 | 0 | 0 | 43% | |
| May 1, 2026 | 5 | 4 | 13 | 0 | 0 | 41% | |
| Apr 1, 2026 | 5 | 4 | 13 | 0 | 0 | 41% | |
| Mar 1, 2026 | 4 | 4 | 14 | 0 | 0 | 36% | |
| Feb 1, 2026 | 3 | 4 | 14 | 0 | 0 | 33% |
Price targets
Where 15 covering analysts think TXG trades over the next 12 months.
$62.13 -33.2% upside Strong Sell
Current$93.00 Low$40.00 Median$60.00 High$90.00 15 analysts
$40.00$90.00
Analyst rating Buy· 2.3/5 as of Oct 2, 2026
Social media sentiment mood -33.3%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
43°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
18 SEC filing reports analyzed · 0 bullish, 7 bearish, 2 mixed, 9 neutral · avg impact 4.3/10.
NEUTRALCLUSTER3/10
Two TXG insiders, including CFO Adam Taich and Director John Stuelpnagel, sold a combined $502K in o
Sep 11, 2026
BEARISH1444/10
Director John R. Stuelpnagel filed a Form 144 notice of intent to sell 20,000 shares of Class A comm
Sep 3, 2026
NEUTRALCLUSTER4/10
A cluster of insider selling at 10x Genomics (TXG) over the past week saw the CEO, CFO, and a direct
Aug 29, 2026
NEUTRALCLUSTER3/10
CEO Serge Saxonov and CFO Adam Taich sold a combined ~$2.25M in open-market sales on August 24, 2026
Aug 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
other
10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative a
Sep 28, 2026
short_volume
Short Volume: TXG — 71.4% short (1.1M / 1.6M)
Short: 1,116,325 | Exempt: 1,100 | TRF Vol: 1,562,678 | Short Ratio: 71.4% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
short_volume
Short Volume: TXG — 62.8% short (0.6M / 1.0M)
Short: 615,661 | Exempt: 9,855 | TRF Vol: 980,029 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_volume
Short Volume: TXG — 68.1% short (1.0M / 1.5M)
Short: 1,001,936 | Exempt: 10,103 | TRF Vol: 1,471,504 | Short Ratio: 68.1% | Off-exchange volume (dark pool + OTC)
Sep 14, 2026
short_volume
Short Volume: TXG — 58.6% short (1.0M / 1.7M)
Short: 1,013,495 | Exempt: 8,611 | TRF Vol: 1,729,825 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.02 | $-0.04–$0.00 | 12.3% | -20.0% | 2↑ 0↓ | $0.1B | 2 |
| Next Q | $-0.01 | $-0.06–$0.05 | -107.1% | -50.2% | 1↑ 1↓ | $0.2B | 2 |
| Current FY | $0.04 | $-0.10–$0.18 | -70.2% | -65.1% | 1↑ 0↓ | $0.6B | 3 |
| Next FY | $0.08 | $0.01–$0.17 | 109.1% | -62.3% | 1↑ 0↓ | $0.7B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.020 | — |
| 7d ago | $-0.017 | -0.003 |
| 30d ago | $-0.017 | -0.003 |
| 60d ago | $-0.037 | +0.017 |
| 90d ago | $-0.037 | +0.017 |
Institutional ownership
Which big funds own TXG (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $3.9B total value (101,234,776 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, ARK. Net buying activity: 27 institutions added/increased vs 23 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 17,629,266 | $675.9M | 17.4% | — |
| BlackRock, Inc. | 10,804,070 | $414.2M | 10.7% | — |
| ARK Investment Management LLC | 10,003,057 | $383.5M | 9.9% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6,982,492 | $267.7M | 6.9% | — |
| Quantinno Capital Management LP | 5,469,698 | $209.7M | 5.4% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,082,594 | $194.9M | 5.0% | — |
| Sumitomo Mitsui Trust Group, Inc. | 4,194,627 | $160.8M | 4.1% | — |
| MORGAN STANLEY | 3,351,911 | $128.5M | 3.3% | ADD +26.2% |
| GOLDMAN SACHS GROUP INC | 3,148,859 | $120.7M | 3.1% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 3,082,790 | $118.2M | 3.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 2,656,353 | 3,351,911 | +26.2% | $128.5M |
| CITADEL ADVISORS LLC | DOUBLED | 743,734 | 2,779,213 | +273.7% | $106.6M |
| Point72 Asset Management, L.P. | NEW | — | 1,852,776 | — | $71.0M |
| Nuveen, LLC | ADD | 625,796 | 1,124,633 | +79.7% | $43.1M |
| JANE STREET GROUP, LLC | NEW | — | 752,999 | — | $28.9M |
| HSBC HOLDINGS PLC | ADD | 285,389 | 537,009 | +88.2% | $20.3M |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | DOUBLED | 165,250 | 445,983 | +169.9% | $17.1M |
| FIRST TRUST ADVISORS LP | DOUBLED | 12,759 | 414,894 | +3151.8% | $15.9M |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | NEW | — | 286,746 | — | $11.0M |
| Trexquant Investment LP | TRIM | 533,288 | 274,176 | -48.6% | $10.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 50 transactions. Net -$15.2M — $0.00 bought, $15.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | Saxonov Serge | Chief Executive Officer | SELL | 2,800 | $82.37 | $230.6K |
| Sep 22, 2026 | Saxonov Serge | Chief Executive Officer | SELL | 9,300 | $80.90 | $752.4K |
| Sep 22, 2026 | Saxonov Serge | Chief Executive Officer | SELL | 9,900 | $81.83 | $810.1K |
| Sep 22, 2026 | Saxonov Serge | Chief Executive Officer | SELL | 1,000 | $78.23 | $78.2K |
| Sep 22, 2026 | Saxonov Serge | Chief Executive Officer | SELL | 2,000 | $79.62 | $159.2K |
| Sep 22, 2026 | SULIMAN SHEHNAAZ | Director | SELL | 1,222 | $82.28 | $100.5K |
| Sep 22, 2026 | SULIMAN SHEHNAAZ | Director | SELL | 2,270 | $81.67 | $185.4K |
| Sep 22, 2026 | SULIMAN SHEHNAAZ | Director | SELL | 1,325 | $80.82 | $107.1K |
| Sep 22, 2026 | SULIMAN SHEHNAAZ | Director | SELL | 292 | $78.20 | $22.8K |
| Sep 22, 2026 | SULIMAN SHEHNAAZ | Director | SELL | 614 | $79.51 | $48.8K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TXG.
Shares short
16,692,300
Settlement Sep 15, 2026
Change vs prior
+3.3%
Semi-monthly cycle
Days to cover
7.1
At avg daily volume
Of shares outstanding
≈12.8%
Estimate — not % of float
All TXG filing & press-release reports (18)
- CLUSTER reportSep 11, 2026
- 144 reportSep 3, 2026
- CLUSTER reportAug 29, 2026
- CLUSTER reportAug 26, 2026
- COURT-RULING reportAug 20, 2026
- INST-CLUSTER reportAug 20, 2026
- CLUSTER reportAug 18, 2026
- INST-CLUSTER reportJul 5, 2026
- 144 reportJun 17, 2026
- CLUSTER reportMay 27, 2026
- DEFA14A reportApr 24, 2026
- CLUSTER reportMar 4, 2026
- CLUSTER reportMar 2, 2026
- CLUSTER reportFeb 27, 2026
- CLUSTER reportFeb 26, 2026
- CLUSTER reportFeb 26, 2026
- CLUSTER reportFeb 25, 2026
- CLUSTER reportFeb 25, 2026